Here's Why Qiagen (QGEN) is a Strong Value Stock

Zacks Investment Research highlights Qiagen N.V. (QGEN) as a strong value stock, currently holding a Zacks Rank #2 (Buy) with a VGM Score of B and a Value Style Score of B, driven by a forward P/E ratio of 19.27. The consensus earnings estimate for fiscal year 2025 has increased by $0.07 to $2.33 per share following eight upward revisions by analysts in the last 60 days, and the company has demonstrated an average earnings surprise of 4.9%.

Analysis

Qiagen N.V. (QGEN) presents as a noteworthy investment candidate within the molecular diagnostics and sample preparation technology space, currently holding a Zacks Rank #2 (Buy). This positive rating is substantiated by a VGM Score of B and a Value Style Score of B, the latter reflecting an attractive forward P/E ratio of 19.27, signaling potential undervaluation. Analyst sentiment for QGEN is robust, with eight analysts revising their earnings estimates upward for fiscal 2025 in the last 60 days. This collective optimism has resulted in a $0.07 increase in the Zacks Consensus Estimate for FY2025, now standing at $2.33 per share. Furthermore, QGEN has demonstrated a consistent ability to exceed market expectations, evidenced by an average earnings surprise of 4.9%. The confluence of a strong buy rating from a recognized research firm, favorable valuation metrics, and positive earnings estimate revisions suggests a constructive outlook for the company.

Key Decisions for Investors

• Investors with a value-oriented approach should consider QGEN, given its Zacks #2 (Buy) rating, B-grade Value score, and a compelling forward P/E ratio of 19.27.
• Monitor Qiagen's upcoming earnings announcements and continued analyst estimate revisions, as the recent positive trend in FY2025 estimates to $2.33 per share is a key bullish indicator.
• Factor in QGEN's consistent track record of delivering an average earnings surprise of 4.9% as a sign of operational efficiency and potential for sustained outperformance.